Fengping Shan - Immune Therapeutics Chief Science Officer
| IMUNDelisted Stock | USD 0.06 0 4.76% |
Executive
Dr. Fengping Shan is Chief Science Officer of the Company. He was our Chief Science Officer since March 2012 and was a member of our Board from March 2012 until September 2014. Dr. Shan has a Ph.D. in Microbiology and Tumor Immunology. Dr. Shan is Professor of Immunology and Vice Director of the Institute of Immunology, China Medical University, in Shenyang, China. He was with the University from 2006 to present. Dr. Shan was the Senior Scientist for Penta Biotech from 2000 to 2006, Chief Scientist for the China Liaoning Institute of Microbiological Science from 1995 to 2000 and studied at the National Cancer Research in Paris, France from 1990 to 1994 since 2014.
| Age | 56 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | 888 613 8802 |
| Web | https://www.immunetherapeutics.com |
Immune Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4526) % which means that it has lost $0.4526 on every $100 spent on assets. This is way below average. Immune Therapeutics' management efficiency ratios could be used to measure how well Immune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 1.08 M in liabilities with Debt to Equity (D/E) ratio of 1.97, which is about average as compared to similar companies. Immune Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Immune Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Immune Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immune Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immune to invest in growth at high rates of return. When we think about Immune Therapeutics' use of debt, we should always consider it together with cash and equity.
Immune Therapeutics, Inc. does not have significant operations. Immune Therapeutics, Inc. is headquartered in Orlando, Florida. Immune Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. Immune Therapeutics [IMUN] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). Management Performance
| Return On Asset | -0.45 |
Immune Therapeutics Leadership Team
Elected by the shareholders, the Immune Therapeutics' board of directors comprises two types of representatives: Immune Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immune. The board's role is to monitor Immune Therapeutics' management team and ensure that shareholders' interests are well served. Immune Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immune Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Phelps, Director | ||
| Peter Aronstam, CFO | ||
| Christopher Pearce, COO, Director | ||
| FMedSci FRACP, Chief RD | ||
| Jack Brewer, Director | ||
| Glen MBA, Chief Officer | ||
| Clifford Selsky, Independent Director | ||
| Nicholas Plotnikoff, Non-Executive Chairman of the Board | ||
| Fengping Shan, Chief Science Officer | ||
| Noreen Griffin, Founder, Chairman and CEO | ||
| Edward Teraskiewicz, Independent Director | ||
| Joseph Fortunak, VP of Global RandD and Chemical Devel. and Member of Advisory Board | ||
| Paul Akin, Independent Director | ||
| Rudy Williams, COO | ||
| Kelly Wilson, Interim Pres |
Immune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Immune Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.45 | |||
| Current Valuation | 83.25 M | |||
| Shares Outstanding | 82.76 M | |||
| Shares Owned By Insiders | 29.51 % | |||
| Price To Earning | 333.33 X | |||
| Price To Sales | 161.50 X | |||
| Gross Profit | 65.83 K | |||
| EBITDA | 3.8 M | |||
| Net Income | 3.59 M | |||
| Cash And Equivalents | 271.53 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Immune Pink Sheet
If you are still planning to invest in Immune Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Therapeutics' history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance |